BACKGROUND AND PURPOSE: The addition of systemic drugs to whole-brain irradiation has not improved the survival of patients with multiple brain metastases, most likely because the agents did not readily cross the blood-brain barrier (BBB). Radiolabeling of cetuximab was performed to investigate whether this antibody crosses the BBB. CASE REPORT: A patient with multiple brain lesions from non-small cell lung cancer was investigated. The largest metastasis (40 x 33 x 27 mm) was selected the reference lesion. On day 1, 200 mg/m(2) cetuximab (0.25% hot and 99.75% cold antibody) were given. On day 3, 200 mg/m(2) cetuximab (cold antibody) were given. Weekly doses of 250 mg/m(2) cetuximab were administered for 3 months. RESULTS: The reference lesion showed enhancement of radiolabeled cetuximab ((123)I-Erbi) on scintigraphy; (123)I-Erbi crossed the BBB and accumulated in the lesion. The reference lesion measured 31 x 22 x 21 mm at 4 months. Enhancement of contrast medium was less pronounced. CONCLUSION: This is the first demonstration of cetuximab crossing the BBB and accumulating in brain metastasis.
BACKGROUND AND PURPOSE: The addition of systemic drugs to whole-brain irradiation has not improved the survival of patients with multiple brain metastases, most likely because the agents did not readily cross the blood-brain barrier (BBB). Radiolabeling of cetuximab was performed to investigate whether this antibody crosses the BBB. CASE REPORT: A patient with multiple brain lesions from non-small cell lung cancer was investigated. The largest metastasis (40 x 33 x 27 mm) was selected the reference lesion. On day 1, 200 mg/m(2) cetuximab (0.25% hot and 99.75% cold antibody) were given. On day 3, 200 mg/m(2) cetuximab (cold antibody) were given. Weekly doses of 250 mg/m(2) cetuximab were administered for 3 months. RESULTS: The reference lesion showed enhancement of radiolabeled cetuximab ((123)I-Erbi) on scintigraphy; (123)I-Erbi crossed the BBB and accumulated in the lesion. The reference lesion measured 31 x 22 x 21 mm at 4 months. Enhancement of contrast medium was less pronounced. CONCLUSION: This is the first demonstration of cetuximab crossing the BBB and accumulating in brain metastasis.
Authors: J P Kleisbauer; D Vesco; J Orehek; B Blaive; C Clary; R Poirier; S Saretto; P Carles; G Dongay; J C Guerin Journal: Eur J Cancer Clin Oncol Date: 1988-02
Authors: P E Postmus; H Haaxma-Reiche; E F Smit; H J Groen; H Karnicka; T Lewinski; J van Meerbeeck; M Clerico; A Gregor; D Curran; T Sahmoud; A Kirkpatrick; G Giaccone Journal: J Clin Oncol Date: 2000-10-01 Impact factor: 44.544
Authors: D Antonadou; M Paraskevaidis; G Sarris; N Coliarakis; I Economou; P Karageorgis; N Throuvalas Journal: J Clin Oncol Date: 2002-09-01 Impact factor: 44.544
Authors: Dirk Rades; Christian Wolff; Roger Nadrowitz; Christian Breunig; Steven E Schild; Manfred Baehre; Birgit Meller Journal: Int J Radiat Oncol Biol Phys Date: 2009-04-06 Impact factor: 7.038
Authors: Dirk Rades; Steven E Schild; Radka Lohynska; Theo Veninga; Lukas J A Stalpers; Juergen Dunst Journal: Cancer Date: 2007-09-01 Impact factor: 6.860
Authors: M Saki; M Toulany; W Sihver; M Zenker; J-M Heldt; B Mosch; H-J Pietzsch; M Baumann; J Steinbach; H P Rodemann Journal: Strahlenther Onkol Date: 2012-08-10 Impact factor: 3.621
Authors: F Manapov; S Klöcking; M Niyazi; C Belka; G Hildebrandt; R Fietkau; G Klautke Journal: Strahlenther Onkol Date: 2011-12-23 Impact factor: 3.621
Authors: Julien Dinkel; Christian Thieke; Christian Plathow; Patrick Zamecnik; Hermann Prüm; Peter E Huber; Hans-Ulrich Kauczor; Heinz-Peter Schlemmer; Christian M Zechmann Journal: Strahlenther Onkol Date: 2011-06-27 Impact factor: 3.621
Authors: M Takagi; K Sakata; M Someya; Y Matsumoto; H Tauchi; M Hareyama; M Fukushima Journal: Strahlenther Onkol Date: 2012-02-11 Impact factor: 3.621
Authors: Maria Caffo; Valeria Barresi; Gerardo Caruso; Mariano Cutugno; Giuseppe La Fata; Mario Venza; Concetta Alafaci; Francesco Tomasello Journal: Int J Mol Sci Date: 2013-01-22 Impact factor: 5.923